Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.54 |
| ▸ | CA2 | P00918 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20821689 | 0.75 | BRDT (0.44) | KDM4EMEN1KMT2AMAOAMAPT | |
| SCHEMBL22376046 | 0.73 | KEAP1 (0.42) | KDM4ETHRBMEN1KMT2AMAPT | |
| SCHEMBL23426703 | 0.72 | BRDT (0.43) | MEN1KMT2AMAPTBRDTPOLB | |
| SCHEMBL20821581 | 0.72 | ALOX5 (0.50) | MAOABRDT | |
| Xanthone SCHEMBL9175420 | 0.71 | MAOA (0.72) | KDM4EMEN1KMT2AMAOAMAPT | |
| SCHEMBL23427074 | 0.71 | BRDT (0.37) | CA1CA2MEN1KMT2AMAPT | |
| SCHEMBL24519053 | 0.71 | BRDT (0.40) | KDM4EMEN1KMT2AMAOAMAPT | |
| SCHEMBL30550557 | 0.71 | GPR3 (0.59) | KDM4EMEN1KMT2AMAOAMAPT | |
| SCHEMBL16553298 | 0.71 | GPR3 (0.59) | KDM4EMEN1KMT2AMAOAMAPT | |
| SCHEMBL4261482 | 0.70 | CA1 (1.00) | CA1CA2KDM4ENTRK1PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176254-A1 | DNA PK INHIBITORS | Kudos Pharmaceuticals Limited (GB) | 2010-04-21 | — | — | EP | disclosed |
| US-20090042865-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| WO-2009010761-A1 | DNA PK INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042865-A1 | DNA-PK INHIBITORS | DNA2, PKN2, TOP1 | CA1 4158/4885CA2 3327/4885KDM4E 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.